Literature DB >> 36245648

The Integration of Diabetic Eye Screening into Hemodialysis Units in Northern Ireland.

Laura N Cushley1,2, Nicola B Quinn1, Peter Blows1, Edward McKeever3, Tunde Peto1,2.   

Abstract

Background: Diabetes is rising globally and is the most common cause of both end-stage renal disease and blindness. People on hemodialysis have to attend several dialysis appointments per week, which can affect their attendance at diabetic eye screening. In addition, previous literature suggests patients on hemodialysis are more likely to have sight-threatening diabetic eye disease. This study aims to determine attendance at the Diabetic Eye Screening Program in Northern Ireland, diabetic retinopathy severity, and use of handheld retinal imaging in people with diabetes attending hemodialysis units in Northern Ireland.
Methods: All patients with diabetes attending hemodialysis clinics regionally were screened and graded by the Diabetic Eye Screening Program in Northern Ireland using a handheld and/or conventional nonmydriatic fundus camera.
Results: All eligible people (N=149) were offered a Diabetic Eye Screening Program in Northern Ireland appointment, 132 attended, 34% of whom had not been seen in >3 years and 15% of whom had never attended the Diabetic Eye Screening Program in Northern Ireland despite multiple previous appointments. Altogether, 13% required urgent referral to hospital eye services, which is significantly higher than the national average of 0.4%. Conclusions: Those on hemodialysis are at high risk for sight-threatening diabetic retinopathy. Implementing the Diabetic Eye Screening Program in Northern Ireland in hemodialysis clinics enables timely diagnosis and referral.
Copyright © 2022 by the American Society of Nephrology.

Entities:  

Keywords:  Northern Ireland; diabetes; diabetes and the kidney; diabetic eye disease; diabetic retinopathy; eye screening; hemodialysis; nephrology

Mesh:

Year:  2022        PMID: 36245648      PMCID: PMC9528388          DOI: 10.34067/KID.0001802022

Source DB:  PubMed          Journal:  Kidney360        ISSN: 2641-7650


  7 in total

1.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.

Authors:  N Sarwar; P Gao; S R Kondapally Seshasai; R Gobin; S Kaptoge; E Di Angelantonio; E Ingelsson; D A Lawlor; E Selvin; M Stampfer; C D A Stehouwer; S Lewington; L Pennells; A Thompson; N Sattar; I R White; K K Ray; J Danesh
Journal:  Lancet       Date:  2010-06-26       Impact factor: 202.731

2.  Ischemic diabetic retinopathy as a possible prognostic factor for chronic kidney disease progression.

Authors:  W J Lee; L Sobrin; M H Kang; M Seong; Y J Kim; J-H Yi; J W Miller; H Y Cho
Journal:  Eye (Lond)       Date:  2014-07-04       Impact factor: 3.775

3.  Factors influencing the onset and progression of diabetic retinopathy in subjects with insulin-dependent diabetes mellitus.

Authors:  G Marshall; S K Garg; W E Jackson; D L Holmes; H P Chase
Journal:  Ophthalmology       Date:  1993-08       Impact factor: 12.079

Review 4.  Diabetic kidney disease; review of the current knowledge.

Authors:  Heshmatollah Shahbazian; Isa Rezaii
Journal:  J Renal Inj Prev       Date:  2013-06-01

Review 5.  The English National Screening Programme for diabetic retinopathy 2003-2016.

Authors:  Peter H Scanlon
Journal:  Acta Diabetol       Date:  2017-02-22       Impact factor: 4.280

6.  Systematic review on barriers and enablers for access to diabetic retinopathy screening services in different income settings.

Authors:  Mapa Mudiyanselage Prabhath Nishantha Piyasena; Gudlavalleti Venkata S Murthy; Jennifer L Y Yip; Clare Gilbert; Maria Zuurmond; Tunde Peto; Iris Gordon; Suwin Hewage; Sureshkumar Kamalakannan
Journal:  PLoS One       Date:  2019-04-23       Impact factor: 3.240

7.  Associated factors of diabetic retinopathy in patients that referred to teaching hospitals in Babol.

Authors:  Seyed Ahmad Rasoulinejad; Karimollah Hajian-Tilaki; Elnaz Mehdipour
Journal:  Caspian J Intern Med       Date:  2015
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.